The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc analysis from the phase 3 SENTRY trial...
Hence then, the article about menarini group reports data from the phase 3 sentry trial of selinexor plus ruxolitinib in myelofibrosis at the european hematology association eha 2026 congress was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress )
Also on site :
- Greg Evigan Shares Sweet ‘My Two Dads’ Throwback With Paul Reiser and Staci Keanan: ‘I Adore These 2 People!’
- Carole King Wrote ‘Will You Love Me Tomorrow’ at 18 and It Became the First No. 1 Song by Any Girl Group; She Sang It 11 Years Later on Tapestry
- Aaron Sorkin Says Jeremy Strong Treated His Co-Stars ‘The Way He Imagines’ Mark Zuckerberg Treats People While Shooting ‘The Social Reckoning’